Delving into the Latest Updates on MAS-825 with Synapse

A Randomized, Placebo-controlled, Parallel-group, Investigator- and Participant-blinded Phase 2a Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in an Adult Population With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

This Phase 2a clinical trial will evaluate the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, or a single s.c. dose of MAS825, to reduce key markers of inflammation related to CVD risk, such as IL-6 and IL-18, in approximately 28 people with known coronary heart disease and TET2 or DNMT3A CHIP (VAF ≥2%).

Start Date15 Feb 2024

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

NCT06309823 / CompletedPhase 3IIT

A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency

MAS825 is a bi-specific IgG1 monoclonal antibody that simultaneously targets IL-1 beta and IL-18, thereby neutralizing both cytokines that are thought to be integral to the pathogenesis of XLP-2. Clinical trials are currently examining its efficacy in other diseases associated with elevations of these cytokines, including NLRC4-associated disease and hidradenitis suppurativa. This study proposes to assess the effectiveness of MAS825 in a single patient with XLP-2, who has previously demonstrated response to blockade of IL-1 beta and IL-18. Given the lack of alternative pharmaceutical options for XLP-2, this represents the only known medication option that avoids the toxicity associated with high-dose corticosteroids and the morbidity associated with hematopoietic stem cell transplantation.

Start Date08 Feb 2023

Sponsor / Collaborator

The Hospital for Sick Children

NCT04641442 / RecruitingPhase 2

A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blind, Placebo-controlled Design to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

This study is a Phase 2 trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in patients with NLRC4-GOF, XIAP deficiency, or CDC42 mutations.

Start Date18 Dec 2020

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

100 Clinical Results associated with MAS-825

Login to view more data

100 Translational Medicine associated with MAS-825

Login to view more data

100 Patents (Medical) associated with MAS-825

Login to view more data

3

Literatures (Medical) associated with MAS-825

02 Apr 2024·Rheumatology

Experience of anti-IL-1β and anti-IL-18 combined therapy (MAS825) in recurrent and recalcitrant macrophage activation syndrome

Article

Author: Sözeri, Betül ; Ulu, Kadir ; Çağlayan, Şengül

13 Oct 2023·Clinical and experimental immunology

Efficacy and safety of MAS825 (anti-IL-1β/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function.

Article

Author: O'Neal, Hollis R ; Hakim, Alex D ; Awili, Mustafa ; Yu, Lili ; Junge, Guido ; Overcash, Jeffrey S ; Jenkins, Janet ; Sengupta, Tirtha ; Watts, Jen ; Rowlands, Marianna ; Lee, Richard ; Stein, Richard R ; Bendrick-Peart, Jamie ; Siddiqi, Omar ; Chauffe, Ann ; Matthews, Jesse ; Patel, Bela ; Koo, Philip ; Kiffe, Michael ; Pachori, Alok ; Waters, Michael ; Hammond, Terese C ; Pinck, Anne ; Jaffrani, Naseem ; Levitch, Rafael ; Waldron-Lynch, Frank ; Criner, Gerard J

MAS825, a bispecific IL-1β/IL-18 monoclonal antibody, could improve clinical outcomes in COVID-19 pneumonia by reducing inflammasome-mediated inflammation. Hospitalized non-ventilated patients with COVID-19 pneumonia (n = 138) were randomized (1:1) to receive MAS825 (10 mg/kg single i.v.) or placebo in addition to standard of care (SoC). The primary endpoint was the composite Acute Physiology and Chronic Health Evaluation II (APACHE II) score on Day 15 or on the day of discharge (whichever was earlier) with worst-case imputation for death. Other study endpoints included safety, C-reactive protein (CRP), SARS-CoV-2 presence, and inflammatory markers. On Day 15, the APACHE II score was 14.5 ± 1.87 and 13.5 ± 1.8 in the MAS825 and placebo groups, respectively (P = 0.33). MAS825 + SoC led to 33% relative reduction in intensive care unit (ICU) admissions, ~1 day reduction in ICU stay, reduction in mean duration of oxygen support (13.5 versus 14.3 days), and earlier clearance of virus on Day 15 versus placebo + SoC group. On Day 15, compared with placebo group, patients treated with MAS825 + SoC showed a 51% decrease in CRP levels, 42% lower IL-6 levels, 19% decrease in neutrophil levels, and 16% lower interferon-γ levels, indicative of IL-1β and IL-18 pathway engagement. MAS825 + SoC did not improve APACHE II score in hospitalized patients with severe COVID-19 pneumonia; however, it inhibited relevant clinical and inflammatory pathway biomarkers and resulted in faster virus clearance versus placebo + SoC. MAS825 used in conjunction with SoC was well tolerated. None of the adverse events (AEs) or serious AEs were treatment-related.

01 Jan 2023·Journal of Clinical Immunology

Improvement of Refractory Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease with Single-Agent Blockade of IL-1β and IL-18

Article

Author: Josephson, Maureen B ; Rood, Julia E ; Burnham, Jon M ; Behrens, Edward M ; Pogoriler, Jennifer ; Finn, Laura S ; Canna, Scott W ; Bar-Or, Amit ; Rezk, Ayman

Systemic juvenile idiopathic arthritis associated with interstitial lung disease (SJIA-LD) represents a highly morbid subset of SJIA for which effective therapies are lacking. We report the case of a patient with refractory SJIA-LD who underwent treatment with MAS-825, an investigational bispecific monoclonal antibody targeting IL-1β and IL-18. MAS-825 treatment was associated with a marked reduction in total IL-18 and free IL-18 in both serum and bronchoalveolar lavage fluid (BAL). Baseline oxygen saturation, exercise tolerance, and quality of life metrics improved after treatment with MAS-825, while pulmonary function testing remained stable. Following treatment, the BAL showed no evidence of pulmonary alveolar proteinosis and inflammatory infiltrates were markedly reduced, reflected by decreased numbers of CD4 T-cells, CD8 T-cells, and macrophages. The patient was able to wean entirely off systemic corticosteroids and other biologics after 10 months of treatment with MAS-825 and experienced no side effects of the drug. This case demonstrates improvement in pulmonary symptoms, lung inflammation, and burden of immunomodulatory therapy after treatment with MAS-825 and suggests that simultaneous targeting of both IL-1β and IL-18 may be a safe and effective treatment strategy in SJIA-LD.

100 Deals associated with MAS-825

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lymphoproliferative Syndrome, X-Linked, 2	Phase 2	CZ	Novartis Pharmaceuticals Corp.	18 Dec 2020
Lymphoproliferative Syndrome, X-Linked, 2	Phase 2	TR	Novartis Pharmaceuticals Corp.	18 Dec 2020
Lymphoproliferative Syndrome, X-Linked, 2	Phase 2	CA	Novartis Pharmaceuticals Corp.	18 Dec 2020
Lymphoproliferative Syndrome, X-Linked, 2	Phase 2	ES	Novartis Pharmaceuticals Corp.	18 Dec 2020
Lymphoproliferative Syndrome, X-Linked, 2	Phase 2	GB	Novartis Pharmaceuticals Corp.	18 Dec 2020
Lymphoproliferative Syndrome, X-Linked, 2	Phase 2	IT	Novartis Pharmaceuticals Corp.	18 Dec 2020
Lymphoproliferative Syndrome, X-Linked, 2	Phase 2	US	Novartis Pharmaceuticals Corp.	18 Dec 2020
Lymphoproliferative Syndrome, X-Linked, 2	Phase 2	JP	Novartis Pharmaceuticals Corp.	18 Dec 2020
COVID-19	Phase 2	US	Novartis Pharmaceuticals Corp.	11 Jun 2020
Respiratory Insufficiency	Phase 2	US	Novartis Pharmaceuticals Corp.	11 Jun 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04382651 (MAS825, Pubmed)	Phase 2	Respiratory Insufficiency C-reactive protein (CRP) \| SARS-CoV-2 presence \| inflammatory markers	138	MAS825	rkeualglfz(kdkijxcynk) = None of the adverse events (AEs) or serious AEs were treatment-related qgabbjctso (fxmlbneedn ) View more	Positive	13 Oct 2023
				Placebo
NCT04382651 (MAS-COVID \| MAS825, CTgov)	Phase 2	COVID-19 \| Respiratory Insufficiency	140	Standard of Care (SoC)+MAS825 (MAS825 + SoC)	hgkkkfgzmt(bgaorhklvv) = zqnhdkkkex riyfurwnnw (ofhglrygzi, aipwtfnlvn - bomnpibuho) View more	-	20 Apr 2022
				Placebo (Placebo + SoC)	hgkkkfgzmt(bgaorhklvv) = zbrxtojtwf riyfurwnnw (ofhglrygzi, ctnmqquiud - sguclduyvu) View more